{
  "docId": "019de070-3a76-76eb-bdcd-70a194f2629a",
  "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 28,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/27",
  "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a",
  "deckJsonHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a.json",
  "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "list",
      "text": "Lead assets in three areas of high unmet medical need; Looking beyond the conventional, redefining the potential of human enzymes to deliver disruptive solutions; Driven by the urgent needs of the communities we serve; Pursuing our vision to become the premier human enzyme company; Changing the lives of patients and their families now and for the future",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e572112-2e47-4c41-880d-f31f1755eea2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.38,
        "x": 0.57,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Pegzilarginase (Pivotal Phase 3, Arginase 1 Deficiency, Metabolism); ACN00177 (Homocystinuria); AEB5100 (Cystinuria, Nephrology)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13f0d9b3-077e-4017-8a31-420c509d8f72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "A Disruptive Platform Producing A New Generation of Human Enzyme Solutions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1b95685-c344-419a-a51b-5f81eb246559",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "58a1fb52-42d3-4870-b62b-c1dce428321b",
      "evidence": "list/bullet: Lead assets in three areas of high unmet medical need; Looking beyond the conventional, redefining the potential of human enzymes to deliver disruptive solutions; Driven by the urgent needs of the communitie",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}